A Phase 2 Study of the Safety and Efficacy of Oral Delafloxacin (DLX) in Community Acquired Pneumonia (CAP)

Trial Profile

A Phase 2 Study of the Safety and Efficacy of Oral Delafloxacin (DLX) in Community Acquired Pneumonia (CAP)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2012

At a glance

  • Drugs Delafloxacin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top